CNIH4: A Potential Drug Target and Biomarker for AMPA Receptor Auxiliary Protein 4

Target Name: CNIH4

NCBI ID: G29097

CNIH4

CNIH4: A Potential Drug Target and Biomarker for AMPA Receptor Auxiliary Protein 4

Abstract

CNIH4 (Cornichon family AMPA receptor auxiliary protein 4) is a highly conserved protein that plays a critical role in the neurotransmitter AMPA (N-acetyl-伪-glutamyl-proline) receptor. The AMPA receptor is involved in the regulation of various cellular processes, including learning, memory, and synaptic plasticity. The dysfunction of the AMPA receptor has been implicated in various neurological disorders, including epilepsy, schizophrenia, and Alzheimer's disease. Therefore, the study of CNIH4 as a potential drug target and biomarker is of great interest.

AMPA (N-acetyl-伪-glutamyl-proline) is a non-competitive N-methyl-D-aspartate (NMDA) receptor antagonist that plays a crucial role in the regulation of synaptic plasticity and learning. The AMPA receptor is composed of two subunits, AMPA-R1 and AMPA-R2, that are expressed in different brain regions and play distinct roles. AMPA-R1 is predominantly expressed in the prefrontal cortex, while AMPA-R2 is mainly expressed in the parietal and subfrontal cortices.

The AMPA receptor functions by forming a complex with the neurotransmitter N-acetyl-伪-glutamyl-proline (AMPA) and the protein N-methyl-D-aspartate (NMDA). The AMPA receptor plays a central role in the regulation of synaptic plasticity, including the formation of new neurons, the modulation of neural activity, and the regulation of learning and memory. The dysfunction of the AMPA receptor has been implicated in various neurological disorders, including epilepsy, schizophrenia, and Alzheimer's disease.

CNIH4: A Critical Protein for the AMPA Receiver

CNIH4 (Cornichon family AMPA receptor auxiliary protein 4) is a highly conserved protein that is expressed in various tissues, including brain, heart, and muscle. It is a member of the Cornichon family, which includes several similar proteins that play a critical role in the regulation of various physiological processes, including neurotransmitter signaling.

CNIH4 is involved in the regulation of the AMPA receptor, which is composed of two subunits, AMPA-R1 and AMPA-R2. The AMPA-R1 subunit is predominantly expressed in the prefrontal cortex, while the AMPA-R2 subunit is mainly expressed in the parietal and subfrontal cortices. The CNIH4 protein interacts with the AMPA receptor and enhances the AMPA receptor's sensitivity to agonists.

CNIH4 is a key regulator of the AMPA receptor, as its dysfunction has been implicated in the development of various neurological disorders. For example, studies have shown that individuals with the CNIH4 gene have reduced AMPA receptor function, which is associated with increased risk of developing epilepsy and schizophrenia. Additionally, CNIH4 has been shown to be involved in the regulation of neural activity, which is critical for the modulation of learning and memory.

Potential Therapeutic Applications

The potential therapeutic applications of CNIH4 as a drug target or biomarker are significant. By modulating the AMPA receptor, CNIH4 can be used to treat various neurological disorders, including epilepsy, schizophrenia, and Alzheimer's disease. Additionally, CNIH4 has been shown to be involved in the regulation of neural activity, which can be used to treat various neurological disorders, including Alzheimer's disease.

CNIH4 has also been shown to play a critical role in the regulation of synaptic plasticity, which is the ability of the brain to

Protein Name: Cornichon Family AMPA Receptor Auxiliary Protein 4

Functions: Involved in G protein-coupled receptors (GPCRs) trafficking from the endoplasmic reticulum to the cell surface; it promotes the exit of GPCRs from the early secretory pathway, likely through interaction with the COPII machinery (PubMed:24405750)

The "CNIH4 Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about CNIH4 comprehensively, including but not limited to:
•   general information;
•   protein structure and compound binding;
•   protein biological mechanisms;
•   its importance;
•   the target screening and validation;
•   expression level;
•   disease relevance;
•   drug resistance;
•   related combination drugs;
•   pharmacochemistry experiments;
•   related patent analysis;
•   advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai

More Common Targets